Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on TEVA stock, giving a Buy rating on January 21.Invest ...

UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for ...

UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...

Diversify Advisory Services LLC raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 2.5% during the fourth quarter, according to its most recent ...

The FDA reported that six patients died after being injected with Teva’s Copaxone or Sandoz’s Glatopa. The US Food and Drug ...

The global Human Growth Hormone Powder Injection market is poised for immense growth, propelled by a surge in chronic diseases and the increasing prevalence ...

Consumer Acne Medicine Market Set For Expansion At 5.31% CAGR, Hitting 12.3 Billion USD By 2032 Galderma, Allergan Prominent drivers of the consumer acne medicine market include rising prevalence of ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...